Same Drug Class

Imatinib vs Pembrolizumab

Imatinib vs Pembrolizumab: Overview

This comparison examines the pharmacological differences between Imatinib and Pembrolizumab.

Mechanism of Action

Imatinib: Selective inhibitor of BCR-ABL, c-Kit, and PDGFR tyrosine kinases.

Pembrolizumab: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.

Pharmacokinetics

Half-life: Imatinib — 18 hours; Pembrolizumab — 26 days.

Chemical Properties

Molecular Formula: Imatinib — C29H31N7O.

Molecular Weight: Imatinib — 493.6030 g/mol.

Type: Imatinib — Small molecule; Pembrolizumab — Antibody.